Overview of clinical trials with glycoprotein IIb-IIIa receptor antagonists in the prevention and management of coronary (Q36179701)

12 August 2017

title

Overview of clinical trials with glycoprotein IIb-IIIa receptor antagonists in the prevention and management of coronary (English)

1 reference

12 August 2017

Winkelmann BR

1

1 reference

12 August 2017

Zahn R

series ordinal

2

1 reference

12 August 2017

Stilz HU

series ordinal

3

1 reference

12 August 2017

language of work or name

English

0 references

publication date

1 November 1997

1 reference

Expert Opinion on Investigational Drugs

12 August 2017

published in

1 reference

12 August 2017

volume

6

1 reference

12 August 2017

issue

11

1 reference

12 August 2017

page(s)

1623-1642

1 reference

Collaborative overview of randomised trials of antiplatelet therapy--I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration

12 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543784.6.11.1623

Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.6.11.1623

A murine monoclonal antibody that completely blocks the binding of fibrinogen to platelets produces a thrombasthenic-like state in normal platelets and binds to glycoproteins IIb and/or IIIa

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.6.11.1623

Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.6.11.1623

Bleeding complications with the chimeric antibody to platelet glycoprotein IIb/IIIa integrin in patients undergoing percutaneous coronary intervention. EPIC Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.6.11.1623

Standard versus low-dose weight-adjusted heparin in patients treated with the platelet glycoprotein IIb/IIIa receptor antibody fragment abciximab (c7E3 Fab) during percutaneous coronary revascularization. PROLOG Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.6.11.1623

Pharmacodynamic study of F(ab')2 fragments of murine monoclonal antibody 7E3 directed against human platelet glycoprotein IIb/IIIa in patients with unstable angina pectoris

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.6.11.1623

Blockade of Platelet GPIIb/IIIa Receptors as an Antithrombotic Strategy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.6.11.1623

Platelet membrane glycoprotein IIb/IIIa: member of a family of Arg-Gly-Asp--specific adhesion receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.6.11.1623

Randomized, double-blind, placebo-controlled dose-ranging study of tirofiban (MK-383) platelet IIb/IIIa blockade in high risk patients undergoing coronary angioplasty

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.6.11.1623

Randomised trial of coronary intervention with antibody against platelet IIb/IIIa iritegrin for reduction of clinical restenosis: results at six months

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.6.11.1623

Increased Risk of Non-Q Wave Myocardial Infarction After Directional Atherectomy Is Platelet Dependent: Evidence From the EPIC Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.6.11.1623

Evidence for Prevention of Death and Myocardial Infarction With Platelet Membrane Glycoprotein IIb/IIIa Receptor Blockade by Abciximab (c7E3 Fab) Among Patients With Unstable Angina Undergoing Percutaneous Coronary Revascularization fn1fn1This study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.6.11.1623

Effects of platelet glycoprotein IIb/IIIa receptor blockade by a chimeric monoclonal antibody (Abciximab) on acute and six-month outcomes after percutaneous transluminal coronary angioplasty for acute myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.6.11.1623

10.1517/13543784.6.11.1623

21 January 2018

Identifiers

DOI

1 reference

12 August 2017

1 reference